Form 4: Cytokinetics Director Acquires Shares Through Equity Program

Cytokinetics Director Robert Arthur Harrington acquired 328 shares of common stock as part of the company's director equity in lieu of cash retainer program.

Summary

• Robert Arthur Harrington, a Director of Cytokinetics Inc. (CYTK), acquired 328 shares of common stock.
• The transaction occurred on July 15, 2025, at a price of $38.01 per share.
• Following this acquisition, Mr. Harrington beneficially owns 22,643 shares of Cytokinetics common stock.
• The acquisition was made under the company's director equity in lieu of cash retainer program.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it reflects a director increasing their stake in the company, aligning their interests with shareholders. However, it is a routine transaction as part of a compensation program, not a discretionary open-market purchase, thus limiting its overall impact on sentiment.

Positives

• A director's acquisition of shares, even as part of a compensation program, indicates alignment of interests with shareholders and confidence in the company's future.

Future Outlook

This Form 4 filing does not provide any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing reports a routine insider transaction related to director compensation, which is specific to Cytokinetics and does not provide broader industry trends or competitive insights.

Corporate Governance

Related Party Transactions

• The acquisition of shares by Director Robert Arthur Harrington from Cytokinetics Inc. as part of a compensation program constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The transaction increases director ownership, potentially signaling confidence in the company's performance and aligning director interests with shareholder value.

Key Dates

Keywords

Cytokinetics, CYTK, Form 4, Insider Transaction, Director Compensation, Stock Acquisition, Equity Program